Are you the publisher? Claim or contact us about this channel

Embed this content in your HTML


Report adult content:

click to rate:

Account: (login)

More Channels


Channel Catalog

Channel Description:

Visit One News Page for Australia news from around the world, aggregated from leading sources including newswires, newspapers and broadcast media. Search millions of archived news headlines. This feed provides the Australia news headlines.

older | 1 | .... | 1428 | 1429 | (Page 1430) | 1431 | 1432 | .... | 1460 | newer

    0 0

    Queensland Cyclone Owen: Powerful system may 'wreak havoc' Symbol copyright EPA Symbol caption Australia’s east coast has been pummelled through heavy rain in contemporary days Australian government have issued a caution about a formidable cyclone this is monitoring in opposition to the coast of Queensland. Cyclone Owen is shifting slowly over waters off the Northern Territory with winds of as much as 200km/h … Reported by The News Articles 32 minutes ago.

    0 0

    Australia lost three key wickets to an improved India attack during a tough middle session on the opening day in the second test on Friday, as the Perth Stadium pitch came roaring to life after lunch. Reported by Reuters India 4 minutes ago.

    0 0

    DGAP-News: Intershop Communications AG / Key word(s): Miscellaneous

    14.12.2018 / 08:55
    The issuer is solely responsible for the content of this announcement.

    *- relaunch of B2B platform to strengthen the customer experience
    - Intershop Commerce-as-a-Service for maximum flexibility
    - rollout to 39 countries within the next months*

    *Jena, Copenhagen, December 14, 2018 *- The ROCKWOOL Group, employer of about 11.000 people in 39 countries, world leader in stone wool solutions and other customized products for industrial applications, decided to boost its digitization efforts by scaling its B2B objectives globally. Therefore, the existing e-commerce solution is to be replaced by Intershop Commerce-as-a-Service.

    As part of a general digitization strategy, the customer touchpoints of sales were a first priority to be adapted to their new requirements. An interaction of CRM, PIM and quotation platform with the dynamic storefront was additionally implemented.

    Mirella Vitale, SVP Marketing, Communication & Public Affairs, ROCKWOOL Group: "With our business running worldwide, being successful in B2B means multi-country, multi-currency, multi-brand management with complex sales channels that need to go hand in hand. We were looking for a commerce solution that allows us to target different channels individually, while being able to scale without effort. Intershop CaaS proved most suited for this purpose."

    Markus Klahn, COO of Intershop adds: "ROCKWOOL is all about sustainability in their products, but in growth in terms of digitization. We are supporting this by rolling out their new e-commerce platform, starting with a pilot in the coming months and expanding it deliberately thereafter with a seamless scalability of each channel."


    *About Intershop Communications AG*

    Intershop Communications AG (founded in Germany 1992; Prime Standard: ISH2) is the leading independent provider of omni-channel commerce solutions. Intershop offers high-performance packaged software for internet sales, complemented by all necessary services. Intershop also acts as a business process outsourcing provider, covering all aspects of online retailing up to fulfillment. Around the globe more than 300 enterprise customers, including HP, BMW, Würth, and Deutsche Telekom run Intershop solutions. Intershop is headquartered in Jena, Germany, and has offices in the United States, Europe, Australia, and China. More information about Intershop can be found online at

    This news release contains forward-looking statements regarding future events or the future financial and operational performance of Intershop. Actual events or performance may differ materially from those contained or implied in such forward-looking statements. Risks and uncertainties that could lead to such difference could include, among other things: Intershop's limited operating history, the unpredictability of future revenues and expenses and potential fluctuations in revenues and operating results, significant dependence on large single customer deals, consumer trends, the level of competition, seasonality, risks related to electronic security, possible governmental regulation, and general economic conditions.

    *Intershop Press Contact*

    Heide Rausch
    Tel: +49.3641.50-1000,,

    14.12.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at --------------------

    Language: English
    Company: Intershop Communications AG
    Intershop Tower
    07740 Jena
    Phone: +49 (0)3641-50-0
    Fax: +49 (0)3641-50-1309
    ISIN: DE000A0EPUH1
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
    End of News DGAP News Service Reported by EQS Group 15 minutes ago.

    0 0

    Australia now recognises west Jerusalem as Israel's capital, Prime Minister Scott Morrison said Saturday, but a contentious embassy shift from Tel Aviv will not occur until a peace settlement is achieved. Reported by News24 2 hours ago.

    0 0

    Over the past 25 years there has been no shortage of ambitious Australian fashion designers who have aimed for the world stage by joining the international catwalk-show circuit and opening international boutiques. Invariably, they have taken on investors to fund their expansion. Some have been extremely successful, a number of them making small fortunes along the way. Many have, however, closed. Japanese-Australian Akira Isogawa took a road less travelled, and his 25-year career... Reported by S.China Morning Post 2 hours ago.

    0 0

    Australia recognises West Jerusalem as capital of Israel Australia has made up our minds to officially recognise West Jerusalem because the capital of Israel, however is not going to transfer its embassy from Tel Aviv till a peace agreement is completed. High minister Scott Morrison stated his country would additionally recognise a long run state of Palestine with East Jerusalem as its capital, … Reported by The News Articles 2 hours ago.

    0 0

    Australia scored some invaluable lower-order runs in the morning session. Reported by DNA 2 hours ago.

    0 0

    Australia now recognises west Jerusalem as Israel's capital, Prime Minister Scott Morrison said Saturday, but a contentious embassy shift from Tel Aviv will not occur until a peace settlement is achieved. Reported by France 24 2 hours ago.

    0 0

    Australia now recognizes west Jerusalem as Israel's capital, Prime Minister Scott Morrison said Saturday, but a contentious embassy shift from Tel Aviv will not occur until a peace… Reported by Japan Today 2 hours ago.

    0 0

    Australia now recognises west Jerusalem as Israel's capital, Prime Minister Scott Morrison said on Saturday, but a contentious embassy shift from Tel Aviv will not occur until a peace settlement is achieved. Reported by Firstpost 2 hours ago.

    0 0

    Prime Minister Scott Morrison says embassy will not move until a peace settlement is achieved. Reported by Al Jazeera 2 hours ago.

    0 0

    The prime minister formally recognized West Jerusalem as the capital of Israel, but said Australia would not move its embassy until a peace settlement is reached. Reported by 1 hour ago.

    0 0

    Australia formally recognises West Jerusalem as Israel's capital, reversing decades of Middle East policy, but will not move its embassy there immediately, Prime Minister Scott Morrison said on Saturday. Reported by Reuters India 1 hour ago.

    0 0

    Roberts, said that the Test cricket Australia play outside the Test championship, which starts July 2019, will be an opportunity to hit and trial Reported by CricBuzz 1 hour ago.

    0 0

    Australia formally recognizes West Jerusalem as Israel's capital, reversing decades of Middle East policy, but will not move its embassy there immediately, Prime Minister Scott Morrison said on Saturday. Reported by Reuters 59 minutes ago.

    0 0

    Australia's lone success after lunch was KL Rahul's wicket early in the session Reported by CricBuzz 42 minutes ago.

    0 0

    The NBA star walked into one of his San Antonio Spurs game wearing a historic Illawarra Hawks indigenous jersey, taking the initiative global. Reported by Brisbane Times 53 minutes ago.

    0 0

    "We look forward to moving our embassy to West Jerusalem when practical... and after final status determination," Australian Prime Minister Scott Morrison told reporters. Reported by euronews 38 minutes ago.

    0 0

    CAMBRIDGE, Mass. and BEIJING, China, Dec. 15, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, announced that updated clinical data from an ongoing Phase 1A/1B trial of tislelizumab, an investigational anti-PD-1 antibody, were presented in an oral session and a poster at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress, being held December 13-16 in Geneva, Switzerland.“We continue to be pleased with the results of tislelizumab in solid tumors,” commented Amy Peterson, M.D., Chief Medical Officer, Immuno-Oncology, at BeiGene. “We believe that these updated results provide support for the continued development of tislelizumab in patients with bladder, esophageal, stomach, liver and non-small cell lung cancers, and we have registration-enabling studies ongoing or planned to start soon in each of these indications.”

    *Summary of ESMO-IO Presentations from the Ongoing Phase 1A/1B Trial*
    The multi-center, open-label Phase 1A/1B trial (NCT02407990) of tislelizumab as monotherapy in advanced solid tumors is being conducted in Australia, New Zealand, the United States, Taiwan and South Korea and consists of dose-escalation and dose-expansion phases in disease-specific cohorts.

    *Updated Results in Patients with Urothelial Carcinoma (UC) *
    Data presented at ESMO-IO included updated results from an analysis of tislelizumab in 17 patients with UC. At the time of the data cutoff on August 31, 2018, median treatment duration was 4.1 months (0.7-30.4 months), with two patients still on treatment.

    Treatment-related adverse events (TRAEs) as assessed by the investigator occurred in 15 patients (88.2%). Of those, fatigue (n=5), infusion-related reactions (n=3), rash (n=3), nausea (n=2), pain in extremity (n=2), peripheral adema (n=2), and proteinuria (n=2) occurred in two or more patients. Three treatment-related Grade 3 or 4 AEs occurred in two patients, fatigue (n=1), and hyperglycemia and latent autoimmune diabetes (n=1). One patient discontinued treatment due to recurrent infusion-related reactions considered related to tislelizumab.

    At the time of the data cutoff, all 17 patients were evaluable for response, defined as having a baseline tumor assessment with at least one post-baseline tumor response assessment, or progression or death. The confirmed response rate was 29.4 percent, with one complete response (CR) and four partial responses (PR). Three additional patients achieved stable disease (SD) as their best response. There was one CR, one PR and one SD among the eight patients with PD-L1 high tumors and two PRs and two SDs among the eight patients with PD-L1 low or negative tumors (one tumor was not-evaluable for PD-L1 expression). The median duration of response was 18.7 months (6.2-18.7 months).  

    *Updated Results in Patients with Esophogeal, Gastric, Hepatocellular and Non-Small Cell Lung Cancers*
    In an oral presentation at ESMO-IO, data on patients with esophageal (EC, n=54), gastric (GC, n=54), hepatocellular (HC, n=50) and non-small cell lung cancers (NSCLC, n=49) were reported.

    TRAEs occurring in at least five percent of patients across all cohorts included fatigue (8.7%), pruritis (7.7%), hypothyroidism (7.2%), decreased appetite (6.8%), rash (6.8%) and nausea (6.3%). Ten patients experienced one or more serious adverse events considered related to tislelizumab, including pneumonitis (n=3) and one case each of acute hepatitis, dermatitis, diarrhea, increased ALT, increased AST, infusion-related reaction, pyrexia and vomiting. Grade 3 or 4 TRAEs occurring in more than one patient included increased AST (n=4), increased ALT (n=3) and pneumonitis (n=2).  There were two fatal TRAEs reported, including acute hepatitis in a patient with HCC confounded by rapidly progressive disease, and pneumonitis in a patient with NSCLC with compromised pulmonary capacity at baseline.

    Confirmed response rates and disease control rates in patients with EC were 11.1 percent and 37.0 percent, respectively; 13.0 percent and 29.6 percent in patients with GC, respectively; 12.2 percent and 51.0 percent in patients with HCC, respectively, and 13.0 percent and 63.0 percent in patients with NSCLC, respectively. For patients with EC and NSCLC, the median duration of response (mDOR) had not been reached. The mDOR in patients with GC was 8.5 months and for patients with HCC it was 15.7 months.

    *About Tislelizumab*
    Tislelizumab (BGB-A317) is an investigational humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.

    Discovered by BeiGene scientists, tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. The new drug application (NDA) for tislelizumab in China for patients with relapsed/refractory (R/R) classical Hodgkin's lymphoma (cHL) has been accepted by the China National Medical Products Administration (NMPA, formerly known as CFDA) and granted priority review status. BeiGene and Celgene Corporation have a global strategic collaboration for the development of tislelizumab in solid tumors in the United States, Europe, Japan and the rest of world outside Asia.

    *About BeiGene*
    BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,700 employees in China, the United States, Australia and Switzerland, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE^® (nanoparticle albumin–bound paclitaxel), REVLIMID^® (lenalidomide), and VIDAZA^® (azacitidine) in China under a license from Celgene Corporation.^i 

    *Forward-Looking Statements*
    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the encouraging clinical data from clinical trials of tislelizumab and BeiGene’s advancement of, and anticipated clinical development, regulatory milestones and commercialization of tislelizumab. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission.  All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

    *Investor Contact*       *Media Contact*
    Craig West       Liza Heapes
    +1 857-302-5189       + 1 857-302-5663

    ^i ABRAXANE^®, REVLIMID^®, and VIDAZA^® are registered trademarks of Celgene Corporation. Reported by GlobeNewswire 35 minutes ago.

    0 0

    Kuldeep Yadav is these days a part of India squad for Australia excursion. © Record Picture/AFP Here is what he tweeted: A message in Chinese language for A Chinaman bowler. Kuldeep Yadav! Glad birthday @imkuldeep18! Have an attractive 12 months forward. — Sachin Tendulkar (@sachin_rt) December 14, 2018 Kuldeep Yadav is … Reported by The News Articles 38 minutes ago.

older | 1 | .... | 1428 | 1429 | (Page 1430) | 1431 | 1432 | .... | 1460 | newer